Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

No longer recruiting (closed or complete)Last updated: 27 October 2025

RESELECT: A trial exploring a new way to improve bone marrow function in people with poor graft function or aplastic anaemiaREscuing bone marrow function in patients with aplaStic anaEmia and bone marrow faiLure post allogEneiC Transplantation (RESELECT): Phase I/II single arm with historical control study assessing the efficacy and safety of Atorvastatin and N-Acetyl Cysteine in the treatment of Poor Graft Function post allogeneic transplantation and relapsed/refractory aplastic anaemia

Trial purpose

Medical clipboardCancer treatment

Tumor type

Blood Cancers Haematological

Age

People17+

Trial acronym

RESELECT

Clinical summary

Summary

This clinical trial is exploring a new treatment approach for people who have trouble producing healthy blood cells due to two conditions:

  • Poor Graft Function (PGF) after a stem cell transplant
  • Relapsed or treatment-resistant Aplastic Anaemia (AA)

Both conditions affect the bone marrow—the part of the body that makes blood cells—and can lead to low levels of red cells, white cells, and platelets.

Researchers believe that problems in the bone marrow’s environment may be contributing to these conditions. Two medications, atorvastatin (commonly used for high cholesterol) and N-acetyl-cysteine (NAC) (used as an antioxidant), may help improve this environment and support better blood cell production.

What the Study Involves

Participants will take:

  • Atorvastatin: 10 mg once daily
  • NAC: 600 mg twice daily
    Both medications are taken by mouth for 12 weeks.

 

The study will monitor how well these medications work and how safe they are. Researchers will check blood tests regularly and ask participants to return medication bottles to help track how consistently the treatment is taken.

Conditions

This trial is treating people with poor graft function or relapsed or refractory aplastic anaemia

Eligibility

Inclusion

1. Poor Graft function OR Relapsed/refractory AA defined as the following
Poor Graft Function:
Two Lineage cytopenias defined as
-Thrombocytopenia
i)Less than or equal to 30x10^9 /L from D40-D60 OR
ii)Less than or equal to 50 x10 ^9/L from D60 onwards
-Neutropenia requiring filgrastim support at any time post D40
-Hb less than or equal to 80g/L
Relapsed /Refractory AA:
Relapse after stem cell transplant OR relapsed post/refractory to 1st line immunosuppression without an unrelated donor identified.
2. Age greater than or equal to 17 years
3. ECOG performance status 0-1
4. Life expectancy > 6 months
5. Patient’s written informed consent

Exclusion

1. Active Grade 3-4 acute GVHD
2. Relapsed or progressive disease on screening bone marrow biopsy or most recent PET imaging.
3. Active second malignancy currently requiring treatment
4. Human Immuno-deficiency Virus (HIV) infection.
5. Any coexisting medical or psychological condition that would preclude participation in the required study procedures.
6. Female patients who are both lactating and breast-feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug
7. Prior history of statin induced myopathy
8. Prior history of severe asthma

Inclusion

  • You have had treatment, but your cancer has come back (relapsed or recurrent).
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have the type of cancer, symptoms, or health risks that this clinical trial is focused on.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

No longer recruiting (closed or complete) hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:

Trial sponsor

The Royal Melbourne Hospital

Scientific Title

REscuing bone marrow function in patients with aplaStic anaEmia and bone marrow faiLure post allogEneiC Transplantation (RESELECT): Phase I/II single arm with historical control study assessing the efficacy and safety of Atorvastatin and N-Acetyl Cysteine in the treatment of Poor Graft Function post allogeneic transplantation and relapsed/refractory aplastic anaemia

Get Support

Peer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Peer Connect

Contact cancer support

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information